Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).

Trial Details

NCT ID

NCT06397222

Phase

PHASE2

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

Sin-Bev-SIRT

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Unresectable HCC (BCLC stage B/C or CNLC II/III) with diagnosis confirmed by histology/cytology or clinically
At least one measurable untreated lesion
Intrahepatic tumors can be treated with 1-2 sessions of SIRT
Child-Pugh score 5-7

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →